Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05923866 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
A Phase 2 study of Multiple System Atrophy (MSA), sponsored by Ono Pharmaceutical Co..
- Active
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 20
- Study locations
NCT05923866 is a Phase 2 study of Multiple System Atrophy (MSA) that is active but no longer recruiting, run by Ono Pharmaceutical Co.. The registered enrollment target is 92 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT05923866, a Phase 2 study of Multiple System Atrophy (MSA), is active but no longer recruiting, sponsored by Ono Pharmaceutical Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ONO-2808
Study Locations (20)
California
- The Parkinson's Movement and Disorder Institute - Fountain Valley
- University of Southern California - Los Angeles
- David Geffen School of Medicine at UCLA - Los Angeles
- Stanford University School of Medicine - Palo Alto
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- Norman Fixel Institute for Neurological Diseases - University of Florida - Gainesville
- Mayo Clinic in Florida - Jacksonville
- University of Miami Miller School of Medicine - Miami
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Michigan
- University of Michigan School of Medicine - Ann Arbor
- Quest Research Institute - Farmington Hills
New York
- NYU Langone Health - NYU Dysautonomia Center - New York
- Icahn School of Medicine at Mount Sinai - New York
Colorado
- CenExel Rocky Mountain Clinical Research - Englewood
Connecticut
- Yale School of Medicine - Yale Church Street Research Unit (CRSU) - New Haven
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05923866
The ClinicalTrials.gov registry entry for NCT05923866 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple System Atrophy (MSA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05923866 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05923866 about?
NCT05923866 is a clinical study titled "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy". This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
What is the current status of trial NCT05923866?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2023-09-22. Estimated completion is 2025-08-31.
What conditions does trial NCT05923866 study?
This clinical trial studies the following conditions: Multiple System Atrophy (MSA).
What interventions are being tested in trial NCT05923866?
The interventions under investigation include: Placebo (DRUG), ONO-2808 (DRUG).
Who is sponsoring clinical trial NCT05923866?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05923866 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy (MSA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.